<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974230</url>
  </required_header>
  <id_info>
    <org_study_id>18CH199</org_study_id>
    <secondary_id>2019-A00284-53</secondary_id>
    <nct_id>NCT03974230</nct_id>
  </id_info>
  <brief_title>Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France.</brief_title>
  <acronym>F3S</acronym>
  <official_title>Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France. The French Fuchs' Follow-up Study, F3S</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyoto University, Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pathophysiology of the most common corneal endothelial dystrophies (Fuchs' Corneal
      Endothelial Dystrophy (FECD)) is beginning to be dismembered. One of the most common genetic
      anomalies is a triplet repetition in one of the introns of the Transcription Factor 4 (TCF4)
      gene located on chromosome 18. However, the number of repetitions varies greatly from one
      patient to another.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intent of that study was to analyse if there is a relationship between the number of
      triplet repetitions and the rate of disease progression. This knowledge would make it
      possible to personalize the care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Year: 0 and 1</time_frame>
    <description>Correlation between visual acuity measured before noon eye by eye of ETDRS scale (international standardized Early Treatment Diabetic Retinopathy Study scale) results and number of CTG triplet repetitions in the intron of the Transcription Factor 4 (TCF4) gene.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CTG triplet repetitions in the intron of the Transcription Factor 4 (TCF4) gene</measure>
    <time_frame>Year: 0 and 1</time_frame>
    <description>Analysis number of CTG triplet repetitions in the intron of the Transcription Factor 4 (TCF4) gene.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mutation rs613872</measure>
    <time_frame>Year: 0 and 1</time_frame>
    <description>Analysis frequency of the mutation rs613872 in the intron of the Transcription Factor 4 (TCF4) gene.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other mutation</measure>
    <time_frame>Year: 0 and 1</time_frame>
    <description>Analysis frequency of the other mutation type nucleotide polymorphisms in the intron of the Transcription Factor 4 (TCF4) gene.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Refraction with the auto-refractor tonometry</measure>
    <time_frame>Year: 0 and 1</time_frame>
    <description>Analysis refraction with the auto-refractor tonometry non-contact air.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ETDRS scale (Early Treatment Diabetic Retinopathy Study scale) in a controlled glare situation</measure>
    <time_frame>Year: 0 and 1</time_frame>
    <description>Correlation between visual acuity measured before noon eye by eye on the ETDRS scale (Early Treatment Diabetic Retinopathy Study scale) in a controlled glare situation.
ETDRS (Early Treatment Diabetic Retinopathy Study) scale will be allowed to measure visual acuity uses an eye chart with 5 letters per line. The scores range from 0 (no letters read correctly) to 100 (all letters read correctly).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interferometry, tear meniscus height, Non Invasive Break-Up Time (NIBUT) and meibography</measure>
    <time_frame>Year: 0 and 1</time_frame>
    <description>Correlation between interferometry, tear meniscus height, Non Invasive Break-Up Time (NIBUT) and meibography results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal thickness in Optical Coherence Tomography (OCT)</measure>
    <time_frame>Year: 0 and 1</time_frame>
    <description>Comparison corneal thickness in Optical Coherence Tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reflectivity results measure by Optical Coherence Tomography (OCT)</measure>
    <time_frame>Year: 0 and 1</time_frame>
    <description>Comparison reflectivity results measure by Optical Coherence Tomography (OCT). Optical Coherence Tomography (OCT) is an imaging technique, which is able to produce, in vivo, cross-sectional images of lesions.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Fuchs Endothelial Corneal Dystrophy</condition>
  <arm_group>
    <arm_group_label>Patients with Fuchs Endothelial Corneal Dystrophy (FECD)</arm_group_label>
    <description>Patients with Fuchs Endothelial Corneal Dystrophy (FECD). They will have a collection of datas and a blood sample.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Witness will be included in control group. They will have a blood sample and slit lamp examination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of datas</intervention_name>
    <description>Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.</description>
    <arm_group_label>Patients with Fuchs Endothelial Corneal Dystrophy (FECD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Blood sample will be performed (genetic analyses).</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Patients with Fuchs Endothelial Corneal Dystrophy (FECD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>slit lamp examination</intervention_name>
    <description>Slit lamp examination will be performed.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample will be performed (genetic analyses).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        There are 2 cohorts: patient and control.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For patient group:

          -  &gt;18 years old

          -  affiliated with or entitled to a social security scheme

          -  having received informed information about the study and having co-signed, with the
             investigator, a consent to participate in the study

          -  with an Fuchs Endothelial Corneal Dystrophy (FECD) certified by slit lamp examination

        For control group:

          -  &gt;18 years old

          -  affiliated with or entitled to a social security scheme

          -  having received informed information about the study and having co-signed, with the
             investigator, a consent to participate in the study

        Exclusion Criteria:

        For patient group:

          -  Patients under guardianship or curatorship

          -  Patient planning to move within the year

          -  With no evidence of ophthalmological pathology requiring intraocular surgery within
             one year of the first visit

          -  Better initial corrected visual acuity &lt;1/10

          -  Not having had intraocular surgery in the 6 months prior to inclusion (after 6 months,
             the endothelium is considered stabilized)

          -  Not having any other progressive pathology responsible for a decrease in visual acuity
             (significant cataract Lens Opacities Classification System (LOCS) &gt;2 ; progressive
             retinal pathology, in particular age-related macular degeneration, unstabilized
             macular edema)

        For control group:

          -  Patients under guardianship or curatorship

          -  with an Fuchs Endothelial Corneal Dystrophy (FECD) certified by slit lamp examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles THURET, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles THURET, MD PhD</last_name>
    <phone>(0)477127540</phone>
    <phone_ext>+33</phone_ext>
    <email>gilles.thuret@univ-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnauld GARCIN, CRA</last_name>
    <phone>(0)477120286</phone>
    <phone_ext>+33</phone_ext>
    <email>Arnauld.Garcin@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-Ã‰tienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles THURET, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe GAIN, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Caroline TRONE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline RONIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas PERRILLAT-COLOMB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cornea</keyword>
  <keyword>Fuchs Endothelial Corneal Dystrophy (FECD)</keyword>
  <keyword>slit lamp</keyword>
  <keyword>Transcription Factor 4 (TCF4)</keyword>
  <keyword>chromosome 18</keyword>
  <keyword>genetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

